News Center

Caught in the Act

October 30th, 2019|

First snapshots of cancer protein B-Raf illuminate basic biology, and can impact drug design for pediatric low grade glioma brain tumor patients.
Researchers at the Blavatnik Institute at Harvard Medical […]

Pediatric Brain Tumor Foundation and American Association for Cancer Research Announce RFP for Research Grant to Optimize Drug Dosing Strategies for PLGA Patients

September 24th, 2019|

The Pediatric Brain Tumor Foundation’s PLGA Fund and the American Association for Cancer Research (AARC) are excited to announce a request for proposals for the inaugural Research Grant to […]

Study Results: New PLGA Research Demonstrates the Power of Teamwork in Improving Outcomes for Kids with Brain Tumors

August 28th, 2019|

Children diagnosed with low-grade astrocytomas, the most common type of pediatric brain tumor, have close to 90 percent overall survival rates. However, the growth of the tumors and the […]

Pediatric Brain Tumor Foundation and A Kids’ Brain Tumor Cure Join Forces to Change the Outcome for All Children with Brain Cancer

November 13th, 2018|

ASHEVILLE, N.C. and BOSTON — The Pediatric Brain Tumor Foundation (PBTF) and A Kids’ Brain Tumor Cure (AKBTC, a/k/a PLGA Foundation) are merging to take a massive leap forward […]

Attainment of Functional and Social Independence in Adult Survivors of Pediatric CNS Tumors: A Report from the St Jude Lifetime Cohort Study

September 17th, 2018|

Beyond survival, achieving independence is a primary goal for adult survivors of pediatric CNS tumors. Researchers at St. Jude recently concluded a comprehensive assessment of independence in survivors of […]

Clinical Trials and Expanded Access to Experimental Drugs/Devices Get a Boost from Recent Legislation

September 4th, 2018|

When you or a family member is diagnosed with a serious or life-threatening disease, you have choices to make about your treatment once standard treatment options are exhausted. Two […]

A Phase I Study of PLX8394 Plus Ritonavir in Children with Recurrent or Progressive BRAF Activated Gliomas

June 13th, 2018|

A Phase I Study of PLX8394 Plus Ritonavir in Children with Recurrent or Progressive BRAF Activated Gliomas

Principal Institutions: Children’s Hospital of Los Angeles in partnership with the Pediatric Brain […]

Scientific and Clinical PLGA Progress: Indebted to the Founding PLGA Scientific Advisors

June 4th, 2018|

Changing the outcome for PLGA patients through cutting-edge scientific and clinical research has finally become a reality.  Thanks, in large part, to the stewardship of the 5-member PLGA Scientific […]

A Phase I/II and Target Validation Study of TAK-580 (MLN2480) for Children with Low-Grade Gliomas and Other RAS/RAF/MEK/ERK Pathway Activated Tumors

May 13th, 2018|

Principal Institutions: Dana Farber Cancer Institute in partnership with the Pacific Pediatric Neuro Oncology Consortium (PNOC).  Oncogenic dysregulation of the RAS/RAF/MEK/ERK pathway has been described in a number of diverse malignancies, […]

Critical Mechanisms of Gene Regulation in Medulloblastoma

May 13th, 2018|

Under the leadership of Dr. Miguel Rivera at Massachusetts General Hospital, this project focuses on medulloblastoma. Medulloblastoma is the most common malignant brain cancer in children and consists of […]